August 20-24, 2018
Grand Hyatt Washington, Washington, DC
Exhibit booth #105
Meet with Flagship at the Next Generation Dx Summit to discover how we help oncology drug developers define their path to success. Our Computational Tissue Analysis (cTA®) approach provides the quantitative, contextual data needed to make confident clinical trials decisions. We partner with drug developers to implement tissue-based biomarker strategies and drive efficient and effective clinical trials.
On Tuesday, August 21, 12:30-1:00 pm, Flagship Chief Scientific Officer Joseph Krueger, Ph.D., will present during the Biomarkers for Cancer Immunotherapy and Combinations program in meeting room Constitution (C, D, E).